Physician profile
Jonathan D Gumer
NPI 1922426162
$4,287.45
in general payments reported to CMS, 2019-2025
7 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $678 · 2023: $678 · 2024: $2,499 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,756 · Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,755.94 |
| Food and Beverage | $1,723.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,118.77 | 2024 | Indigo System, Penumbra System |
| Medtronic, INC. | $1,359.40 | 2022-2025 | Endurant Iis, Heli-Fx Endoanchor System, Valiant Captivia |
| Abbott Laboratories | $405.07 | 2022-2023 | Jeti, Jeti Peripheral Catheter |
| Silk Road Medical, INC. | $176.99 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $155.78 | 2021-2024 | |
| Inari Medical, INC. | $50.84 | 2022 | |
| Smith+Nephew, INC. | $20.60 | 2023 | Stravix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.